Chenghua Weng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chenghua Weng has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Zhichun Liu
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Soochow University
4 shared publications Gang Wang
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Soochow University, Suzhou, P.R. China
2 shared publicationsLei Zhang
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Soochow University, Suzhou, P.R. China
2 shared publicationsLeixi Xue
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications- Zhichun Liu
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications - Chenchu Yan
The Fourth Affiliated Hospital of Soochow University, Institutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, and
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
The TWEAK–HOIP–HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation
Cellular proliferation is intrinsically coupled to metabolic reprogramming, a conserved biological association that modulates the progression of diverse proliferative pathologies. In the present study, we unveil a novel mechanistic link between tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) signaling and Human antigen R (HuR)‐driven metabolic alterations in lupus nephritis (LN), a progressive renal disorder characterized by mesangial cells (MCs) hyperproliferation and glomerular dysfunction. We demonstrate that TWEAK stimulation elicits linear ubiquitination of AMP‐activated protein kinase (AMPK)—a master regulator of cellular energy metabolism—mediated by the E3 ubiquitin ligase HOIL‐1‐interacting protein (HOIP). This posttranslational modification directly results in the functional inactivation of AMPK. Notably, suppressed AMPK activity drives the nuclear export of HuR, a ubiquitously expressed RNA‐binding protein, leading to its subsequent accumulation in the cytoplasmic compartment. In the cytosol, HuR selectively binds to and stabilizes the mRNAs of key cell cycle regulators, with Cyclin D1 being a primary target. This stabilization of Cyclin D1 mRNA ultimately promotes aberrant MCs proliferation, a pathological hallmark of LN. To validate the functional relevance of the pathogenesis, we performed HOIP knockdown experiments in MCs. Consistent with our mechanistic model, HOIP depletion significantly restored AMPK phosphorylation (a well‐established surrogate marker of AMPK activation), suppressed HuR cytoplasmic shuttling, reduced Cyclin D1 expression at both the transcriptional and translational levels, and ultimately inhibited aberrant MCs proliferation in vitro. Collectively, our results establish the TWEAK–HOIP–AMPK–HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1)
Open AccessThe TWEAK–HOIP–HuR Axis: A Novel Mechanism of AMPK Inactivation and Metabolic Reprogramming in Lupus Nephritis Mesangial Cells Hyperproliferation
Cellular proliferation is intrinsically coupled to metabolic reprogramming, a conserved biological association that modulates the progression of diverse proliferative pathologies. In the present study, we unveil a novel mechanistic link between tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) signaling and Human antigen R (HuR)‐driven metabolic alterations in lupus nephritis (LN), a progressive renal disorder characterized by mesangial cells (MCs) hyperproliferation and glomerular dysfunction. We demonstrate that TWEAK stimulation elicits linear ubiquitination of AMP‐activated protein kinase (AMPK)—a master regulator of cellular energy metabolism—mediated by the E3 ubiquitin ligase HOIL‐1‐interacting protein (HOIP). This posttranslational modification directly results in the functional inactivation of AMPK. Notably, suppressed AMPK activity drives the nuclear export of HuR, a ubiquitously expressed RNA‐binding protein, leading to its subsequent accumulation in the cytoplasmic compartment. In the cytosol, HuR selectively binds to and stabilizes the mRNAs of key cell cycle regulators, with Cyclin D1 being a primary target. This stabilization of Cyclin D1 mRNA ultimately promotes aberrant MCs proliferation, a pathological hallmark of LN. To validate the functional relevance of the pathogenesis, we performed HOIP knockdown experiments in MCs. Consistent with our mechanistic model, HOIP depletion significantly restored AMPK phosphorylation (a well‐established surrogate marker of AMPK activation), suppressed HuR cytoplasmic shuttling, reduced Cyclin D1 expression at both the transcriptional and translational levels, and ultimately inhibited aberrant MCs proliferation in vitro. Collectively, our results establish the TWEAK–HOIP–AMPK–HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.
- Open Access
- 8 October 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-15
Single-cell sequencing reveals distinct peripheral immune responses in anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease
Anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis (MDA5+ DM) is an autoimmune disease related to rapidly progressive interstitial lung disease (RPILD) with high mortality. However, the pathogenesis of MDA5+ DM with RPILD remains unclear. We aimed to explore the peripheral immune landscape of MDA5+ DM with RPILD using single-cell RNA sequencing (scRNA-seq). We performed scRNA-seq of peripheral blood mononuclear cells (PBMCs) from MDA5+ DM with RPILD (n = 4), MDA5+ DM with ILD (non-RPILD, n = 3), and healthy controls (HCs, n = 3). The proportion of CD14+ monocytes increased, but the proportion of natural killer cells, CD4+ T cells and CD8+ T cells decreased in MDA5+ DM with RPILD compared with HCs. Obvious antiviral response was the main feature of MDA5+ DM with RPILD, and the expression of several interferon-stimulated genes (ISGs) related to RIG-I pathway increased, including IRF7, DDX60, IFI27 and IFI6. However, this antiviral response was not significant in MDA5+ DM with ILD. In addition, multiple immune pathways were downregulated in MDA5+ DM with RPILD, including antigen processing and presentation, translation initiation, mRNA splicing, and activation of T and B cells. Cell communication analysis revealed that multiple signaling pathways, including MHC-I and MHC-II, were attenuated in MDA5+ DM with RPILD. Notably, MHC-II signaling was absent in CD4+ naïve T cells from MDA5+ DM with RPILD. This study demonstrates that antiviral response plays an important role in the pathogenesis of MDA5+ DM with RPILD, as well as changes in downstream immune pathways, providing potential therapeutic targets for future treatment.
- 8 October 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-15
Open AccessSingle-cell sequencing reveals distinct peripheral immune responses in anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease
Anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis (MDA5+ DM) is an autoimmune disease related to rapidly progressive interstitial lung disease (RPILD) with high mortality. However, the pathogenesis of MDA5+ DM with RPILD remains unclear. We aimed to explore the peripheral immune landscape of MDA5+ DM with RPILD using single-cell RNA sequencing (scRNA-seq). We performed scRNA-seq of peripheral blood mononuclear cells (PBMCs) from MDA5+ DM with RPILD (n = 4), MDA5+ DM with ILD (non-RPILD, n = 3), and healthy controls (HCs, n = 3). The proportion of CD14+ monocytes increased, but the proportion of natural killer cells, CD4+ T cells and CD8+ T cells decreased in MDA5+ DM with RPILD compared with HCs. Obvious antiviral response was the main feature of MDA5+ DM with RPILD, and the expression of several interferon-stimulated genes (ISGs) related to RIG-I pathway increased, including IRF7, DDX60, IFI27 and IFI6. However, this antiviral response was not significant in MDA5+ DM with ILD. In addition, multiple immune pathways were downregulated in MDA5+ DM with RPILD, including antigen processing and presentation, translation initiation, mRNA splicing, and activation of T and B cells. Cell communication analysis revealed that multiple signaling pathways, including MHC-I and MHC-II, were attenuated in MDA5+ DM with RPILD. Notably, MHC-II signaling was absent in CD4+ naïve T cells from MDA5+ DM with RPILD. This study demonstrates that antiviral response plays an important role in the pathogenesis of MDA5+ DM with RPILD, as well as changes in downstream immune pathways, providing potential therapeutic targets for future treatment.
- Open Access
- 29 April 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (11)
Lactate programs PBX1 lactylation and mesangial proliferation in lupus nephritis
Lupus nephritis (LN) constitutes the most common organ-threatening manifestation of systemic lupus erythematosus (SLE), with the pathological proliferation of mesangial cells (MCs) recognized as a critical factor in its pathogenesis and progression. Self-DNA-containing immune complex (DNA-IC) represents a prime pathogenic factor in SLE, yet its pathological effect on MCs remains unclear. In the present study, we elucidated the mechanism underlying the excessive proliferation of MCs following the recognition of DNA-IC in patients with LN. Here, we pinpointed that the excessive proliferation of MCs was attributed to an anomalous transition from the G 1 to the S phase of the cell cycle in patients with LN. Mechanically, the dysfunction of P27 protein resulted in the aberrant G 1 -S phase transition, and the phenomenon was closely related to the ubiquitin-mediated degradation of its key transcription factor, PBX1. This degradation was regulated by lactylation of PBX1 in the site of Lys40 residue. The elevated lactylation level of PBX1 protein was caused by the upregulation of glycolysis levels induced by DNA-IC. Accordingly, targeting lactate production in MCs from patients with LN effectively alleviated their renal inflammation and fibrosis progression. Elevated lactate resulted in PBX1 lactylation, leading to excessive proliferation of MCs and, thus, serving as a promising therapeutic target for LN.
- 29 April 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (11)
Open AccessLactate programs PBX1 lactylation and mesangial proliferation in lupus nephritis
Lupus nephritis (LN) constitutes the most common organ-threatening manifestation of systemic lupus erythematosus (SLE), with the pathological proliferation of mesangial cells (MCs) recognized as a critical factor in its pathogenesis and progression. Self-DNA-containing immune complex (DNA-IC) represents a prime pathogenic factor in SLE, yet its pathological effect on MCs remains unclear. In the present study, we elucidated the mechanism underlying the excessive proliferation of MCs following the recognition of DNA-IC in patients with LN. Here, we pinpointed that the excessive proliferation of MCs was attributed to an anomalous transition from the G 1 to the S phase of the cell cycle in patients with LN. Mechanically, the dysfunction of P27 protein resulted in the aberrant G 1 -S phase transition, and the phenomenon was closely related to the ubiquitin-mediated degradation of its key transcription factor, PBX1. This degradation was regulated by lactylation of PBX1 in the site of Lys40 residue. The elevated lactylation level of PBX1 protein was caused by the upregulation of glycolysis levels induced by DNA-IC. Accordingly, targeting lactate production in MCs from patients with LN effectively alleviated their renal inflammation and fibrosis progression. Elevated lactate resulted in PBX1 lactylation, leading to excessive proliferation of MCs and, thus, serving as a promising therapeutic target for LN.
- Open Access
- 18 February 2023
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (3) , 635-648
Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case–Control Study
Introduction Interstitial lung disease (ILD) is a common complication of dermatomyositis (DM) and one of the main risk factors for poor prognosis in DM patients. The aim of this study was to reveal the clinical characteristics of DM patients with ILD. Methods Clinical data from the Second Affiliated Hospital of Soochow University were used to conduct a retrospective case–control study. Univariate and multivariate logistic regression analysis were performed to identify risk factors for ILD in DM. Results A total of 78 DM patients were included in this study, including 38 DM patients with ILD and 40 DM patients without ILD. Compared with patients without ILD, patients with ILD were older (59.6 vs. 51.2 years, P = 0.004), and had higher rates of clinically amyopathic DM (CADM) (45 vs. 20%, P = 0.019), Gottron’s papules (76 vs. 53%, P = 0.028), mechanic’s hands (13 vs. 0%, P = 0.018), myocardial involvement (29 vs. 8%, P = 0.014), and higher positive rates of anti-SSA/Ro52 (74 vs. 20%, P < 0.001) and anti-melanoma differentiation-associated gene-5 (MDA5) (24 vs. 8%, P = 0.048) antibodies, while albumin (ALB) (34.5 vs. 38.0 g/l, P = 0.006), prognostic nutritional index (PNI) (40.3 vs. 44.7, P = 0.013), the rates of muscle weakness (45 vs. 73%, P = 0.013) and heliotrope rash (50 vs. 80%, P = 0.005) were lower. In addition, the five patients who died were all DM patients with ILD (13 vs. 0%, P = 0.018). Multivariate logistic regression showed that old age (odds ratio [OR] = 1.119, 95% confidence interval [CI] = 1.028–1.217, P = 0.009), Gottron’s papules (OR = 8.302, 95% CI = 1.275–54.064, P = 0.027) and anti-SSA/Ro52 (OR = 24.320, 95% CI = 4.102–144.204, P < 0.001) were independent risk factors for ILD in DM. Conclusions DM patients with ILD usually present with older age, higher rates of CADM, Gottron's papules, mechanic’s hands, myocardial involvement, higher positive rates of anti-MDA5 and anti-SSA/Ro52 antibodies, lower ALB, PNI, and lower rates of muscle weakness and heliotrope rash. Old age, Gottron’s papules, and anti-SSA/Ro52 were independent risk factors for ILD in DM.
- 18 February 2023
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (3) , 635-648
Open AccessClinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case–Control Study
Introduction Interstitial lung disease (ILD) is a common complication of dermatomyositis (DM) and one of the main risk factors for poor prognosis in DM patients. The aim of this study was to reveal the clinical characteristics of DM patients with ILD. Methods Clinical data from the Second Affiliated Hospital of Soochow University were used to conduct a retrospective case–control study. Univariate and multivariate logistic regression analysis were performed to identify risk factors for ILD in DM. Results A total of 78 DM patients were included in this study, including 38 DM patients with ILD and 40 DM patients without ILD. Compared with patients without ILD, patients with ILD were older (59.6 vs. 51.2 years, P = 0.004), and had higher rates of clinically amyopathic DM (CADM) (45 vs. 20%, P = 0.019), Gottron’s papules (76 vs. 53%, P = 0.028), mechanic’s hands (13 vs. 0%, P = 0.018), myocardial involvement (29 vs. 8%, P = 0.014), and higher positive rates of anti-SSA/Ro52 (74 vs. 20%, P < 0.001) and anti-melanoma differentiation-associated gene-5 (MDA5) (24 vs. 8%, P = 0.048) antibodies, while albumin (ALB) (34.5 vs. 38.0 g/l, P = 0.006), prognostic nutritional index (PNI) (40.3 vs. 44.7, P = 0.013), the rates of muscle weakness (45 vs. 73%, P = 0.013) and heliotrope rash (50 vs. 80%, P = 0.005) were lower. In addition, the five patients who died were all DM patients with ILD (13 vs. 0%, P = 0.018). Multivariate logistic regression showed that old age (odds ratio [OR] = 1.119, 95% confidence interval [CI] = 1.028–1.217, P = 0.009), Gottron’s papules (OR = 8.302, 95% CI = 1.275–54.064, P = 0.027) and anti-SSA/Ro52 (OR = 24.320, 95% CI = 4.102–144.204, P < 0.001) were independent risk factors for ILD in DM. Conclusions DM patients with ILD usually present with older age, higher rates of CADM, Gottron's papules, mechanic’s hands, myocardial involvement, higher positive rates of anti-MDA5 and anti-SSA/Ro52 antibodies, lower ALB, PNI, and lower rates of muscle weakness and heliotrope rash. Old age, Gottron’s papules, and anti-SSA/Ro52 were independent risk factors for ILD in DM.
- 1 May 2021
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 29 (5) , 783-784
Response to: “Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain? The tip of an iceberg!”
- 1 May 2021
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 29 (5) , 783-784
Response to: “Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain? The tip of an iceberg!”
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 13
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to at least one disease-modifying antirheumatic drug (DMARD). PubMed, Embase, Cochrane library and ClinicalTrials.gov were searched for relevant randomized controlled trials (RCTs) from inception to April 2020. The active drugs included three JAK inhibitors and eight bDMARDs while the control drugs included placebo or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Outcomes include American College of Rheumatology 20% response (ACR20), Disease Activity Score in 28 joints (DAS28), Health Assessment Questionnaire–Disability Index (HAQ-DI) and discontinuations for adverse events (AEs). We estimated summary odds ratios (ORs) and weighted mean differences (WMDs) using network meta-analysis with random effects. Eighty-eight RCTs with 31,566 patients were included. All JAK inhibitors and bDMARDs were more effective than placebo in ACR20 (ORs ranging between 3.05 and 5.61), DAS28 (WMDs ranging between −1.91 and −0.80) and HAQ-DI (WMDs ranging between −0.34 and −0.21). Tocilizumab, certolizumab pegol and upadacitinib showed relatively good efficacy in these three outcomes according to their relative ranking. Notably, tocilizumab was more effective than other active drugs in DAS28 (WMDs ranging between −1.11 and −0.49). Compared with the lower recommended doses, increasing the doses of JAK inhibitors (baricitinib 4 mg versus 2 mg, tofacitinib 10 mg versus 5 mg and upadacitinib 30 mg versus 15 mg) cannot provide significant additional benefits. In terms of discontinuations for AEs, all active drugs showed no significant difference compared with placebo except certolizumab pegol [OR 1.65, 95% credible interval (CrI) 1.06–2.61] and rituximab (3.17, 1.11–10.80). Tocilizumab, certolizumab pegol and upadacitinib may have relatively good efficacy in patients with RA after treatment failure with csDMARDs. RA patients taking a JAK inhibitor may have a preference for a lower recommended dose.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 13
Open AccessComparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to at least one disease-modifying antirheumatic drug (DMARD). PubMed, Embase, Cochrane library and ClinicalTrials.gov were searched for relevant randomized controlled trials (RCTs) from inception to April 2020. The active drugs included three JAK inhibitors and eight bDMARDs while the control drugs included placebo or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Outcomes include American College of Rheumatology 20% response (ACR20), Disease Activity Score in 28 joints (DAS28), Health Assessment Questionnaire–Disability Index (HAQ-DI) and discontinuations for adverse events (AEs). We estimated summary odds ratios (ORs) and weighted mean differences (WMDs) using network meta-analysis with random effects. Eighty-eight RCTs with 31,566 patients were included. All JAK inhibitors and bDMARDs were more effective than placebo in ACR20 (ORs ranging between 3.05 and 5.61), DAS28 (WMDs ranging between −1.91 and −0.80) and HAQ-DI (WMDs ranging between −0.34 and −0.21). Tocilizumab, certolizumab pegol and upadacitinib showed relatively good efficacy in these three outcomes according to their relative ranking. Notably, tocilizumab was more effective than other active drugs in DAS28 (WMDs ranging between −1.11 and −0.49). Compared with the lower recommended doses, increasing the doses of JAK inhibitors (baricitinib 4 mg versus 2 mg, tofacitinib 10 mg versus 5 mg and upadacitinib 30 mg versus 15 mg) cannot provide significant additional benefits. In terms of discontinuations for AEs, all active drugs showed no significant difference compared with placebo except certolizumab pegol [OR 1.65, 95% credible interval (CrI) 1.06–2.61] and rituximab (3.17, 1.11–10.80). Tocilizumab, certolizumab pegol and upadacitinib may have relatively good efficacy in patients with RA after treatment failure with csDMARDs. RA patients taking a JAK inhibitor may have a preference for a lower recommended dose.
- 1 June 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (6) , 721-734
Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis
- 1 June 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (6) , 721-734
Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis